Business Context and Reporting Period
This Form 8-K is filed by AcelRx Pharmaceuticals, Inc. (ACRX) on May 22, 2020, reporting events occurring on May 18 and May 20, 2020. The Company is a Delaware corporation focused on pharmaceutical development, specifically regarding its product Zalviso.
Key Financial Metrics and Agreements
- Historical Performance: For the years ended December 31, 2018 and 2019, the cost of goods sold under the Supply Agreement with Grünenthal GmbH exceeded net sales due to manufacturing costs surpassing the contractual sales price.
- Original Deal Value: The terminated License Agreement included $50.0 million in upfront and milestone payments already received, with eligibility for approximately $194.5 million in additional regulatory and sales-based milestones.
- Royalty Structure: The agreement provided for tiered royalties and fees in the mid-teens to mid-twenties percent range on net sales.
- Royalty Monetization: In September 2015, the Company sold majority royalty rights to PDL BioPharma, Inc. for $65.0 million in gross proceeds. PDL receives 75% of Territory royalties and 80% of the first four commercial milestones (capped at $195.0 million).
Material Changes
- Termination of Agreements: Grünenthal GmbH notified the Company on May 18, 2020, of its decision to terminate the Collaboration and License Agreement and the Manufacture and Supply Agreement, effective on or about November 14, 2020.
- Reversion of Rights: Upon termination, rights to market and sell Zalviso in the European Union, Switzerland, Liechtenstein, Iceland, Norway, and Australia will revert immediately to AcelRx.
- New Negotiations: On May 20, 2020, the Company granted a right of first negotiation (ROFN) to a third party currently negotiating a license for DZUVEO in Europe, to replace the Grünenthal agreement.
Outlook, Risks, and Management Commentary
- Supply Terms: Management intends to negotiate revised supply terms for Zalviso under any new agreement to address the historical issue where manufacturing costs exceeded sales prices.
- Monetization Obligations: Due to the expected termination, the Company is contractually obligated under the Royalty Monetization agreement to use commercially reasonable efforts to negotiate a replacement license with a third party.
- Risk: The termination creates uncertainty regarding future revenue streams from the European market and the ability to secure a replacement partner that meets the financial thresholds required by the PDL BioPharma agreement.
Investor Verification Checklist
- Verify the status of negotiations with the third party granted the right of first negotiation for the European market.
- Confirm the specific timeline for the reversion of Zalviso marketing rights on November 14, 2020.
- Assess the impact of the termination on the $65.0 million royalty monetization deal with PDL BioPharma and potential clawback or adjustment clauses.
- Review the Company's cash position and liquidity given the loss of the Grünenthal supply arrangement and the historical negative margin on Zalviso sales.